Literature DB >> 21070202

Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.

N L Ward1, C M Loyd, J A Wolfram, D Diaconu, C M Michaels, T S McCormick.   

Abstract

BACKGROUND: There is ongoing debate regarding the initiation of psoriatic plaque as primarily arising from an anomaly in epidermal keratinocytes (KCs) or from abnormalities in immunocytes that secondarily activate otherwise normal KCs. In mice engineered to overexpress the angiopoietin receptor Tie2 in KCs, skin spontaneously develops the characteristic clinical, histological and immune cell phenotypes of psoriasis which can be reversed with either transgene repression or ciclosporin administration, suggesting key roles for both KCs and T cells in mediating the skin disease in this murine model.
OBJECTIVES: To determine if antigen-presenting cells (APCs) and macrophages alone are sufficient to sustain psoriasiform inflammation in the KC-Tie2 murine model of psoriasis.
METHODS: Clodronate liposomes were intradermally injected into involved dorsal skin of KC-Tie2 or control animals once a week for 6weeks and acanthosis, angiogenesis, immune cell infiltration and cytokine production were quantitated using immunohistochemistry and interactive image analyses, enzyme-linked immunosorbent assay (ELISAs) and quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: Clodronate liposome injection eliminated CD11c+, F4/80+ and CD11b+ cells in the skin and returned CD8+ T-cell numbers to control mouse levels. APC depletion in KC-Tie2 mouse skin resulted in resolution of the acanthotic skin phenotype, decreased dermal angiogenesis, and a return to control mouse levels for interleukin (IL)-1α, IL-6, IL-23 and tumour necrosis factor (TNF)-α expression and modest reductions in interferon-γ and IL-17.
CONCLUSIONS: These findings suggest a critical role for APCs and myeloid cell-derived IL-23 and TNF-α and underscore the importance of Th1 and Th17 T cells in maintaining the psoriasiform skin phenotype in the KC-Tie2 mouse model.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21070202      PMCID: PMC3051033          DOI: 10.1111/j.1365-2133.2010.10129.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  43 in total

1.  Overexpression of amphiregulin in the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype.

Authors:  P W Cook; M R Pittelkow; M Piepkorn
Journal:  J Invest Dermatol       Date:  1999-11       Impact factor: 8.551

2.  Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function.

Authors:  N Jones; D Voskas; Z Master; R Sarao; J Jones; D J Dumont
Journal:  EMBO Rep       Date:  2001-05       Impact factor: 8.807

3.  Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter.

Authors:  I Diamond; T Owolabi; M Marco; C Lam; A Glick
Journal:  J Invest Dermatol       Date:  2000-11       Impact factor: 8.551

4.  Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.

Authors:  Yu-Ping Xia; Baosheng Li; Donna Hylton; Michael Detmar; George D Yancopoulos; John S Rudge
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

5.  A randomized trial of etanercept as monotherapy for psoriasis.

Authors:  Alice B Gottlieb; Robert T Matheson; Nicholas Lowe; Gerald G Krueger; Sewon Kang; Bernard S Goffe; Anthony A Gaspari; Mark Ling; Gerald D Weinstein; Anjuli Nayak; Kenneth B Gordon; Ralph Zitnik
Journal:  Arch Dermatol       Date:  2003-12

6.  Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder.

Authors:  Allen G Li; Donna Wang; Xin-Hua Feng; Xiao-Jing Wang
Journal:  EMBO J       Date:  2004-04-01       Impact factor: 11.598

7.  Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate.

Authors:  Ritva Ylitalo; Heimo Syvälä; Pentti Tuohimaa; Pauli Ylitalo
Journal:  Pharmacol Toxicol       Date:  2002-03

8.  TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2.

Authors:  Manolis Pasparakis; Gilles Courtois; Martin Hafner; Marc Schmidt-Supprian; Arianna Nenci; Atiye Toksoy; Monika Krampert; Matthias Goebeler; Reinhard Gillitzer; Alain Israel; Thomas Krieg; Klaus Rajewsky; Ingo Haase
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

9.  Etanercept as monotherapy in patients with psoriasis.

Authors:  Craig L Leonardi; Jerold L Powers; Robert T Matheson; Bernard S Goffe; Ralph Zitnik; Andrea Wang; Alice B Gottlieb
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.

Authors:  Edmund Lee; William L Trepicchio; Judith L Oestreicher; Debra Pittman; Frank Wang; Francesca Chamian; Madhav Dhodapkar; James G Krueger
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  34 in total

1.  Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye.

Authors:  Delu Zhou; Ying-Ting Chen; Feeling Chen; Marianne Gallup; Trinka Vijmasi; Ahmad F Bahrami; Lisa B Noble; Nico van Rooijen; Nancy A McNamara
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

2.  Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.

Authors:  Wanhong Ding; Michela Manni; Lori L Stohl; Xi K Zhou; John A Wagner; Richard D Granstein
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

Review 3.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

4.  Fcγ receptor III and Fcγ receptor IV on macrophages drive autoimmune valvular carditis in mice.

Authors:  Patricia M Hobday; Jennifer L Auger; Gregory R Schuneman; Stefanie Haasken; J Sjef Verbeek; Bryce A Binstadt
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

5.  Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C+IL-6KO Mice.

Authors:  Yi Fritz; Philip A Klenotic; William R Swindell; Zhi Qiang Yin; Sarah G Groft; Li Zhang; Jaymie Baliwag; Maya I Camhi; Doina Diaconu; Andrew B Young; Alexander M Foster; Andrew Johnston; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2016-10-27       Impact factor: 8.551

6.  VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 mice.

Authors:  Doina Diaconu; Yi Fritz; Sean M Dawes; Candace M Loyd; Nicole L Ward
Journal:  J Dermatol Sci       Date:  2013-08-17       Impact factor: 4.563

7.  Depletion of inflammatory dendritic cells with anti-CD209 conjugated to saporin toxin.

Authors:  Michael N Alonso; Josh G Gregorio; Matthew G Davidson; Joseph C Gonzalez; Edgar G Engleman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

8.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08

9.  Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.

Authors:  Andrew Johnston; Yi Fritz; Sean M Dawes; Doina Diaconu; Paul M Al-Attar; Andrew M Guzman; Cynthia S Chen; Wen Fu; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward
Journal:  J Immunol       Date:  2013-01-28       Impact factor: 5.422

10.  Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation.

Authors:  Jackelyn B Golden; Sarah G Groft; Michael V Squeri; Sara M Debanne; Nicole L Ward; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2015-07-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.